Halaven eribulin mesylate dose, indications, adverse. Research paper eribulin mesylate in pretreated breast. Eribulin mesylate e7389 mesylate, a synthetic analogue of halichondrin b in phase iii clinical trials for breast cancer, binds to tubulin and microtubules. The efficacy of eribulin mesylate for patients with cutaneous. Clinical trials are research studies that involve people. Perez, ahmad awada, louise yelle, susan mccutcheon, peter a. Healthrelated quality of life in patients with locally. For the treatment of patients with locally advanced breast cancer labc or metastatic breast cancer mbc, who have progressed after at least two chemotherapeutic regimens for advance disease. Calculation of the individual dose to be administered to a patient should be based on the strength of the ready to use solution that contains 0. We report a patient with extended progressionfree survival pfs of more than 57 months with metastatic breast carcinoma treated with eribulin in the thirdline setting. The efficacy of eribulin mesylate for patients with. This openlabel, multicenter phase ii study was designed to evaluate the efficacy and safety of eribulin as a first or secondline treatment for patients with metastatic breast. Nurse hub for metastatic breast cancer halaven eribulin.
Phase ii study of eribulin mesylate e7389 in patients pts with locally advanced or metastatic breast cancer mbc previously treated with anthracycline, taxane. The clinical trials on this list are studying eribulin mesylate. Eribulin injection comes as a solution liquid to be given intravenously into a vein over 2 to 5 minutes by a doctor or nurse in a medical office, infusion center, or hospital. Oct 22, 2019 calculation of the individual dose to be administered to a patient should be based on the strength of the ready to use solution that contains 0. It is used to treat certain patients with breast cancer and liposarcoma. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at g2m phase, and, potentially, tumor regression. Eribulin mesylate is one of the most recent agents introduced in the pharmacological armamentarium for the. Highlights of prescribing information halaven information. Each vial contains 1 mg of eribulin mesylate as a 0. Eribulin mesylate halaven is an antitubulin antimitotic agent with distinct microtubule endbinding properties that result. Eribulin is a synthetic analogue of halichondrin b, which inhibits microtubule polymerization by a mechanism distinct from other available antitubulin agents. Eribulin inhibits the formation of mitotic spindles and blocks cell cycle progression at the g. Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates.
Patient resources and links halaven eribulin mesylate. Healthrelated quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an openlabel randomized phase 3 trial javier cortes. Some tubulinbinding drugs are known to have antivascular antiangiogenesis or vasculardisrupting activities that can target abnormal tumor vessels. Eribulin mesylate use as thirdline therapy in patients. Eribulin is a nontaxane microtubule dynamics inhibitor, belonging to a new class of antineoplastic agents, the halichondrin class. Halaven, eribulin eribulin is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action. Halaven contains eribulin mesylate, a microtubule dynamics inhibitor. It is used in patients who have already been treated with at least 2 types of chemotherapy for metastatic disease, including an anthracycline and a taxane. It is used in patients who have already been treated with at least 2 types of chemotherapy for. Pdf eribulin mesylate eribulin, an analog of the marine natural product halichondrin b, is a. Eribulin mesylate for treatment of metastatic breast cancer. The recommended regimen for eribulin mesylate comprises intravenous administration of 1. Both eribulin and diol 21 were then submitted to the nci for further evaluation.
Eribulin mesylate was positive in mouse lymphoma mutagenesis assays, and was clastogenic in an in vivo rat bone marrow micronucleus assay. Learn about drug imprint, side effects, uses treating, dosage, interaction, overdose, and warnings. Dec 10, 2019 halaven eribulin mesylate injection, for intravenous use 0. Eribulin monotherapy versus treatment of physicians choice. Halaven injection eribulin mesylate side effects, images. All trials on the list are supported by nci ncis basic information about clinical trials explains the types and phases of trials and how they are carried out. Research paper eribulin mesylate in pretreated breast cancer. Apexbio eribulin mesylate javascript seems to be disabled in your browser. Download zip file who is halaven eribulin mesylate injection for.
Halaven is a prescription medicine used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other types of anticancer medicines after the cancer has spread. Eribulin mesylate is currently indicated as a sequential monotherapy to be administered after two chemotherapeutic regimens, including anthracycline and taxane treatments, for treatment of. Clinical trials using eribulin mesylate national cancer. In recent years, survival of women with metastatic breast cancer has improved because of advances in cancerspecific therapy and supportive care. It has a mean volume of distribution of 43 to 114 lm2 and human plasma protein binding ranges from 49 to 65%. Metastatic breast cancer who have previously received at least two. Longterm response with eribulin mesylate in a breast cancer. Eribulin monotherapy versus treatment of physicians. Nov 14, 2015 healthrelated quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an openlabel randomized phase 3 trial javier cortes, stacie hudgens, chris twelves, edith a. Eribulin mesylate is a structurally simplified synthetic analogue of halichondrin b a natural product isolated from the marine sponge halichondria okadai. Eribulin mechanism of action is different from other tubulintargeting agents such as taxanes, vinca alkaloids, epothilones. Fertility studies have not been conducted with eribulin mesylate in humans or animals. Eribulin mesylate is a synthetic macrocyclic ketone analog of the marine sponge natural product halichondrin b and an inhibitor of microtubule dynamics. Resources for mbc patients halaven eribulin mesylate hcp.
Pdf first global approval of eribulin mesylate for treatment of. Sep 16, 2014 eribulin mesylate is a synthetic macrocyclic ketone analog of the marine sponge natural product halichondrin b and an inhibitor of microtubule dynamics. A 48yearold lady was diagnosed with stage iia pt2n0m0, high grade, triple. Phase ii study of eribulin mesylate e7389 in patients pts with locally advanced or metastatic breast cancer mbc previously treated. Eribulin mesylate, a nontaxane, completely synthetic microtubule inhibitor, has recently been approved by the u. Eisai a synthetic analogue of the marine natural product halichondrin b that interferes with microtubule dynamics was approved in november 2010 by the us food.
All trials on the list are supported by nci ncis basic information about clinical trials. Phase ii trial of eribulin mesylate in recurrent or. If this drug is used during pregnancy, or if a patient becomes pregnant while taking. Eribulin mesylate was approved for treatment of heavily pretreated patients with mbc based on results of the study 305embrace. Halaventm eribulin mesylate page 1 of 29 product monograph prhalaventm eribulin mesylate injection 0. Unchanged eribulin was the major circulating species after the administration of radiolabeled eribulin to patients. Pdf eribulin mesylate reduces tumor microenvironment. Eribulin inhibits the formation of mitotic spindles and blocks cell cycle. Currently there are 5 active patents in the united states that are associated with the. This study examined the microtubule inhibitor eribulin in recurrentmetastatic salivary gland cancers rmsgcs, a disease where no therapeutic standard exists. Dec 05, 2017 eribulin mesylate was positive in mouse lymphoma mutagenesis assays, and was clastogenic in an in vivo rat bone marrow micronucleus assay. Sequential cohorts of 36 patients received eribulin mesilate 25min intravenous administration according to schedule 1 1. Advanced cas patients previously treated with taxane scheduled for erb use were enrolled.
Eribulin mesylate is a synthetic analogue of halichondrin b, a product isolated from the marine sponge, halichondria okadai. Eribulin mesylate halaven is a chemotherapy agent used to treat metastatic breast cancer by interfering with the growth of crucial intracelluar structures. In a clinical study of more than 750 women, halaven was compared with other chemotherapies or hormone therapies commonly used to treat metastatic breast cancer mbc. Fungal laccases are well investigated enzymes with high potential in different applications like bleaching of waste materials waters and textiles, cellulose delignification, and organic synthesis.
Eribulin mesylate use as thirdline therapy in patients with. Eribulin mesylate, 1, halaven, previously e7389, nsc 707389, and er086526 is an antitubulin antimitotic agent with distinct microtubule endbinding properties that result in inhibition of. Halaven eribulin dosing, indications, interactions, adverse. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization. Find halaven resources and downloads to help support you and your third line. Eribulin is a nontaxane microtubule inhibitor approved for the treatment of metastatic breast carcinoma after two prior chemotherapeutic regimens. Breast cancer that has metastasized spread to other parts of the body.
Although some women lived longer and some women did not live as long, women who were treated with halaven lived, on average, 25% longer. Food and drug administration as thirdline treatment of metastatic breast cancer refractory to anthracyclines and taxanes. Eribulin mesylate is a chemotherapeutic medicine approved to treat metastatic breast cancer, an advanced form of breast cancer that has spread to other parts of the body microtubules are dynamic. Lw6 324adamantan1ylphenoxyacetylamino4hydroxybenzoic acid methyl ester is a potent inhibitor of drug efflux by the breast cancer level of resistance proteins bcrp. Eribulin is an anticancer drug marketed by eisai co. Halaven eribulin dosing, indications, interactions. Cureus third line eribulin for triplenegative metastatic. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Eribulin is an analogue of halichondrin b, a substance derived from a marine sponge lissodendoryx sp. Eribulin mesylate reduces tumor microenvironment abnormality. Phase ii, multicenter, singlearm, feasibility study of eribulin. Peripheral neuropathy is a common doselimiting adverse effect of microtubule inhibitors, including eribulin. Structurally eribulin is a simplified and synthetically produced version of halichondrin b, a natural product isolated from the marine sponge halichondria okadai.
183 1652 1015 1228 505 1152 1657 974 808 1007 1289 551 666 1031 1533 1431 696 792 293 1220 1287 1428 1320 191 149 1363 1402 1016 874 1119 1544 613 722 1546 92 1109 507 597 412 1092 1129 1421 1114 861 1180